Antimalarial Iron Chelator, FBS0701, Shows Asexual and Gametocyte Plasmodium falciparum Activity and Single Oral Dose Cure in a Murine Malaria Model
Public Deposited- Creator
- Ferrer, Patricia
- Tripathi, Abhai K.
- Clark, Martha A.
- Hand, Carla Cerami
- Rienhoff, Hugh Young
- Sullivan, David J.
- Abstract
- Iron chelators for the treatment of malaria have proven therapeutic activity in vitro and in vivo in both humans and mice, but their clinical use is limited by the unsuitable absorption and pharmacokinetic properties of the few available iron chelators. FBS0701, (S)3”-(HO)-desazadesferrithiocin-polyether [DADFT-PE], is an oral iron chelator currently in Phase 2 human studies for the treatment of transfusional iron overload. The drug has very favorable absorption and pharmacokinetic properties allowing for once-daily use to deplete circulating free iron with human plasma concentrations in the high µM range. Here we show that FBS0701 has inhibition concentration 50% (IC50) of 6 µM for Plasmodium falciparum in contrast to the IC50 for deferiprone and deferoxamine at 15 and 30 µM respectively. In combination, FBS0701 interfered with artemisinin parasite inhibition and was additive with chloroquine or quinine parasite inhibition. FBS0701 killed early stage P. falciparum gametocytes. In the P. berghei Thompson suppression test, a single dose of 100 mg/kg reduced day three parasitemia and prolonged survival, but did not cure mice. Treatment with a single oral dose of 100 mg/kg one day after infection with 10 million lethal P. yoelii 17XL cured all the mice. Pretreatment of mice with a single oral dose of FBS0701 seven days or one day before resulted in the cure of some mice. Plasma exposures and other pharmacokinetics parameters in mice of the 100 mg/kg dose are similar to a 3 mg/kg dose in humans. In conclusion, FBS0701 demonstrates a single oral dose cure of the lethal P. yoelii model. Significantly, this effect persists after the chelator has cleared from plasma. FBS0701 was demonstrated to remove labile iron from erythrocytes as well as enter erythrocytes to chelate iron. FBS0701 may find clinically utility as monotherapy, a malarial prophylactic or, more likely, in combination with other antimalarials.
- Date of publication
- 2012
- Keyword
- Beta-Thalassemia
- Q
- Red Cells
- Hematology
- Pharmacokinetics
- Drug Absorption
- Malaria
- Science
- Drug Research and Development
- Alpha-Thalassemia
- Animal Models
- Drugs and Devices
- Biology
- Plasmodium Falciparum
- Parasitic Diseases
- Hemoglobinopathies
- Model Organisms
- Research Article
- Medicine
- R
- Transfusion Medicine
- Drug Discovery
- Mouse
- Infectious Diseases
- DOI
- Identifier
- PMID: 22629364
- Onescience id: b59c036a1180fb8f31a6879f7e1cb05b258939ac
- Publisher DOI: https://doi.org/10.1371/journal.pone.0037171
- PMCID: PMC3357340
- Resource type
- Article
- Rights statement
- In Copyright
- Journal title
- PloS One
- Journal volume
- 7
- Journal issue
- 5
- Page start
- e37171
- Language
- English
- ISSN
- 1932-6203
Relations
- Parents:
- In Collection:
This work has no parents.
Items
| Thumbnail | Title | Date Uploaded | Visibility | Actions |
|---|---|---|---|---|
|
|
EuropePMC-PMC3357340.pdf | 2020-10-31 | Public | Download |